Class-leading device technology

Vectura has deep expertise applied to its approved devices and across its innovative pipeline, spanning the complete range of inhalation delivery types. These include cost-effective DPI and pMDI devices, through to smart nebulisers optimised for targeted lung delivery of a wide range of active drug doses. In particular, Vectura’s differentiated smart nebuliser technology has the potential to provide significant improvement in delivery efficiency, efficacy and/or reduction in treatment time over conventional nebulisers.

Comprehensive enabling formulation technology

In addition to our industry-leading device platforms, Vectura has outstanding formulation capabilities to match. Our deep expertise provides us with competitive advantage in the development of generics for asthma and COPD. Beyond this, we can leverage our proprietary particle engineering technologies, or skills in liquid formulation, to develop innovative products. These can be based on the significantly enhanced delivery of known respiratory molecules, or by re-purposing established drugs – normally delivered orally or via injection – in inhaled format to treat niche diseases.

Advanced analytical capability

Vectura’s advanced in-house analytical capability cements the company’s ability to support all phases of inhalation product development. Vectura has extensive state-of-the-art analytical testing facilities and equipment, and an expert analytical workforce able to fully develop and validate all methods required to characterise complex inhalation products, not just for small molecules and combinations thereof but also for complex biologic inhalation products.

Facilities, laboratories and manufacturing suites

We have the expertise to develop manufacturing processes ranging in scale from laboratory testing all the way through to commercially relevant scale-up, including the manufacture of clinical supplies for large-scale clinical studies. This enables us to offer a seamless transfer out to commercial manufacturing sites.

Scale-up and industrialisation capabilities

Vectura has the expertise to develop manufacturing processes for pMDI products, ranging in scale from small laboratory, all the way through to commercially relevant scale, offering a seamless transition and transfer out to commercial product manufacturing sites.

Airways disease regulatory and clinical expertise

Vectura has a strong team of experienced professionals in all development-related disciplines required for taking drugs and drug-device combinations from pre-clinical development right through to regulatory submission (MAA – Marketing Authorisation Application or NDA – New Drug Application) and post-approval.